MECHNIKOV Institute is a
Project for the transfer of influenza vaccine technology, construction and equipment of the biotechnological products manufacturing site in Managua, Republic of Nicaragua.

Our production capacity is up to 30 million doses of influenza vaccine per season. We are the only biotech plant in Central America built in accordance with WHO requirements and GMP standards.
April 27, 2014

Celebration of the Memorandum between SPbSRIVS of Russia and INSS of Nicaragua.

July 12, 2014

Meeting of the Presidents of Russia and Nicaragua.
February 2015

Set up of the company.
March 23-26, 2015

First Session of the PAHO Technical Committee on influenza vaccine technology transfer to Nicaragua (CECMED, Cuba).
May-June 2015

Inspection of the influenza vaccine manufacturing facility of "SPbSRIVS" by CECMED, Cuba.
November - December 2015

Foundation stone layed and Start of construction of the MECHNIKOV Institute Plant.
February 2016

GMP and market certifiactiona are granted in the name of "SPbSRIVS" by CECMED, Cuba (NRA).

April 2016

Inscription of "SPbSRIVS" as a supplier to PAHO Revolving Fund.

October 22, 2016

Inaguration of Institute Mechnikiov manufacturing facility.

November 2016

Start of commissioning and adjustment, validation and certification works of the MECHNIKOV Institute Plant.

January 2019

Integral GMP inspection of the Institute MECHNIKOV is conducted by NRA of Cuba - CECMED.
March 2019

GMP Certificate is granted to Institute MECHNIKOV.
April 2019

Start of manufacturing, of the first commercial batches of the influenza vaccine.
The Institute is preparing to become a first covid vaccine manufacturing site in Central-America by introducing Convacell vaccine.
To date, the MECHNIKOV Institute is manufacturing three vaccines, Flu-M, Flu-M Tetra and Inactivated Split Influenza Vaccine, thus protecting the populations of LAC from influenza outbreaks.